





# Bendamustine is a Safe and Effective Lymphodepletion Agent for Axicabtagene Ciloleucel in Patients with Refractory or Relapsed Large B-Cell Lymphoma

**Summary** *Bendamustine* is a **safe and effective** alternative lymphodepletion conditioning for axi-cel with **comparable outcomes, lower early hematological toxicity, favorable immune reconstitution,** and **comparable expansion kinetics** as compared to fludarabine in combination with cyclophosphamide (FC) in patients receiving axicabtagene ciloleucel therapy for relapsed/refractory LBCLs.

**Study Design** Retrospective, single center from Stanford University  Inverse probability of treatment weights applied  Patients with relapsed or refractory DLBCL treated with axi-cel  CD4 and CD8 CAR-T cells measured @ 7, 14, 21, 28 days following infusion

**Population**  **84** patients FC (n=57) Bendamustine (n=27) IPTW variables

Age at Transfusion	Sex	Bridging therapy before LD
IPI at apheresis	Prior Auto SCT	ALC at Leukapheresis
Pre-LD ALC	Pre-LD ANC	Pre-LD Platelets
Pre-LD LDH		

